Mayo Foundation for Medical Education and Research

University of California

Purna C Kashyap

Michael A Fischbach

Brianna B Williams

Sahil Khanna

Vanessa L Hale

Darrell S Pardi

Eric J Battaglioli

This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

Methods and materials for using ruminococcus gnavus or clostridium sporogenes to treat gastrointestinal disorders

This document provides methods and materials involved in assessing and/or treating a mammal having a functional gastrointestinal disorder (FGID) such as irritable bowel syndrome (IBS). For example, methods and materials provided herein can be used for determining if a mammal having a FGID is likely to respond to a particular FGID treatment. This document also provides methods and materials for treating a mammal having a FGID.

Assessing and treating functional gastrointestinal disorders

Methods and materials for usingorto treat gastrointestinal disorders

This document provides biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility toinfection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection

Provided herein are biomarkers that can be altered in the gut of a mammal having CDI. One or more biomarkers can be used to predictinfection (CDI) treatment outcome (e.g., response to primary CDI treatment and/or risk of recurrence after primary CDI treatment) in a mammal (e.g., a human) having CDI. Methods for using one or more biomarkers can be used to predict response to primary CDI treatment in a mammal having CDI. Methods for using one or more biomarkers can be used to predict risk of recurrence in a mammal having CDI. Also provided are methods of treating CDI.

Growing community of inventors

Rochester, MN, United States of America

Purna C Kashyap